| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Shares of Cryolife (NYSE:CRY) rose 2.9% in after-market trading after the company reported Q2 results.
Earnings per share rose 700.00% year over year to $0.12, which beat the estimate of ($0.05).
Revenue of $76,148,000 higher by 41.62% from the same period last year, which beat the estimate of $70,970,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Date: Jul 29, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/n236vtq7
Company's 52-week high was at $32.34
Company's 52-week low was at $16.13
Price action over last quarter: down 6.07%
Cryolife Inc is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures focused on aortic repair. The company has two reportable segments namely Medical devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue, On-X products, JOTEC products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular tissues. It generates a majority of its revenue from the Medical Devices segment. Geographically, the company generates a majority of its revenue from the United States.
Posted In: CRY
